Pioneering A New Children’s Food Allergy Treatment

With the evolution of biotechnology, addressing allergy treatments for children offers hope for a future where the young can lead lives unrestricted by common food allergens. 

A pre-clinical stage Biotech Company aimed to develop its first product for novel food allergy treatment in children through clinical proof of concept before partnering with a global pharmaceutical firm and its currently raising capital to support pre-clinical development program. 

With the collaborative assistance of Biointelect, the company’s venture to secure investors was strategically streamlined, ensuring their pioneering approach to children’s food allergy treatments was robustly supported, well-researched, and optimally positioned in the market.

Nanoparticle Drug Reformation: A Biointelect Product Development Strategy

With oncology treatments rapidly growing in interest, the quest to refine and perfect drug delivery mechanisms is paramount. Utilising nanoparticles, a biotech company stands on the verge of reformulating three approved oncology drugs, targeting the expansive US and EU markets. 

Biointelect has played a critical role in sculpting the company’s strategy, from inception to investor readiness. It is with Biointelect’s assistance that the biotech company could pivot from concept to a formidable market contender, with a clear and strategic vision for investor engagement.

Bringing Nuvaxovid™ to Market: A Novavax Case Study

Introduction In the dynamic world of biotechnology, the intersection of passion and knowledge often paves the path for revolutionary breakthroughs. Since 2014, Biointelect have supported Novavax – a global company advancing protein-based vaccines with its Matrix-M™ adjuvant based in Gaithersburg, Md., U.S. –  since 2014 (phase 1) with Australian and New Zealand medical affairs, policy, […]

Developing a Winning Business Case: Securing NHMRC Grant for an Antibiotic Solution

Antibiotic resistance is a looming global health challenge, with the ESKAPE pathogens leading the charge. Amid this urgent need, a university research group has broken new ground with a patented product that promises to dismantle this resistance. 

Biointelect’s partnership was enlisted to bolster their pursuit of the esteemed NHMRC Development Grant, offering an integrated approach leading to a strengthened grant application, optimised strategy, and subsequently, successful grant acquisition.

Bringing Antimalarial Tafenoquine To US and Australian Markets

Antimalarial drugs have been instrumental in saving millions of lives. Yet, with the rise of resistance to existing medications, there emerges a critical need for innovative treatments and increased accessibility to newfound medications.

With this difficult mission in mind, US pharmaceutical company 60 Degree Pharmaceuticals (60P) enlisted the strategic service of Biointelect to introduce Tafenoquine (TQ) to the United States and Australian markets.

Through a virtual drug development model, Biointelect’s joint efforts with 60P spanned four years and helped to redefine antimalarial drug availability in these markets. This partnership saw first prophylactic antimalarial drug approval by the FDA and TGA in nearly two decades.